Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +3.96% | +5.88% | -44.93% |
Financials (USD)
Sales 2024 * | 410M | Sales 2025 * | 465M | Capitalization | 1B |
---|---|---|---|---|---|
Net income 2024 * | 63M | Net income 2025 * | 99M | EV / Sales 2024 * | 2.44 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.16 x |
P/E ratio 2024 * |
12.6
x | P/E ratio 2025 * |
8.04
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.36% |
Latest transcript on Ironwood Pharmaceuticals, Inc.
1 day | +3.96% | ||
1 week | +5.88% | ||
1 month | -18.71% | ||
3 months | -33.19% | ||
6 months | -36.36% | ||
Current year | -44.93% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas McCourt
CEO | Chief Executive Officer | 66 | 08-12-31 |
Sravan Emany
DFI | Director of Finance/CFO | 46 | 21-12-05 |
Marcel Moulaison
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alexander Denner
BRD | Director/Board Member | 54 | 20-11-08 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-12-02 |
Mark Currie
BRD | Director/Board Member | 69 | 18-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.50% | 28 M€ | -1.00% | ||
0.42% | 25 M€ | -2.35% | - | |
0.35% | 1,085 M€ | +9.05% | - | |
0.20% | 43 M€ | +4.17% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 6.3 | +3.96% | 2,883,238 |
24-05-30 | 6.06 | +0.50% | 1,543,445 |
24-05-29 | 6.03 | +2.55% | 2,497,024 |
24-05-28 | 5.88 | -1.18% | 1,611,879 |
24-05-24 | 5.95 | -1.82% | 1,913,464 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.93% | 1B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- IRWD Stock